JPH0337708B2 - - Google Patents
Info
- Publication number
- JPH0337708B2 JPH0337708B2 JP13693982A JP13693982A JPH0337708B2 JP H0337708 B2 JPH0337708 B2 JP H0337708B2 JP 13693982 A JP13693982 A JP 13693982A JP 13693982 A JP13693982 A JP 13693982A JP H0337708 B2 JPH0337708 B2 JP H0337708B2
- Authority
- JP
- Japan
- Prior art keywords
- liver
- peaks
- serum
- peak
- liquid chromatography
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 238000000034 method Methods 0.000 claims description 39
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 33
- 208000019423 liver disease Diseases 0.000 claims description 29
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 claims description 13
- 239000001099 ammonium carbonate Substances 0.000 claims description 13
- 235000012501 ammonium carbonate Nutrition 0.000 claims description 13
- 238000004811 liquid chromatography Methods 0.000 claims description 13
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 10
- 239000012472 biological sample Substances 0.000 claims description 9
- 239000000463 material Substances 0.000 claims description 6
- 238000012856 packing Methods 0.000 claims description 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 6
- 239000000377 silicon dioxide Substances 0.000 claims description 5
- 210000002966 serum Anatomy 0.000 description 23
- 230000001575 pathological effect Effects 0.000 description 19
- 238000004458 analytical method Methods 0.000 description 18
- 239000000306 component Substances 0.000 description 13
- 230000002159 abnormal effect Effects 0.000 description 12
- 208000006454 hepatitis Diseases 0.000 description 12
- 239000000523 sample Substances 0.000 description 12
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 10
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 8
- 238000003745 diagnosis Methods 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 208000019425 cirrhosis of liver Diseases 0.000 description 7
- 238000001514 detection method Methods 0.000 description 7
- 206010008909 Chronic Hepatitis Diseases 0.000 description 6
- 239000007864 aqueous solution Substances 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 239000000945 filler Substances 0.000 description 6
- 238000004128 high performance liquid chromatography Methods 0.000 description 6
- 235000018102 proteins Nutrition 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 210000002700 urine Anatomy 0.000 description 5
- 231100000354 acute hepatitis Toxicity 0.000 description 4
- 238000012742 biochemical analysis Methods 0.000 description 4
- 238000010876 biochemical test Methods 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 229940109239 creatinine Drugs 0.000 description 4
- 231100000283 hepatitis Toxicity 0.000 description 4
- 210000003494 hepatocyte Anatomy 0.000 description 4
- 208000017169 kidney disease Diseases 0.000 description 4
- 201000007270 liver cancer Diseases 0.000 description 4
- 208000014018 liver neoplasm Diseases 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 3
- 108010082126 Alanine transaminase Proteins 0.000 description 3
- 238000001574 biopsy Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 230000007170 pathology Effects 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 206010008635 Cholestasis Diseases 0.000 description 2
- 206010016654 Fibrosis Diseases 0.000 description 2
- 206010019663 Hepatic failure Diseases 0.000 description 2
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 2
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 2
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 2
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 2
- 231100000359 cholestasis Toxicity 0.000 description 2
- 230000007870 cholestasis Effects 0.000 description 2
- 230000007882 cirrhosis Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000005229 liver cell Anatomy 0.000 description 2
- 208000007903 liver failure Diseases 0.000 description 2
- 231100000835 liver failure Toxicity 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 230000007310 pathophysiology Effects 0.000 description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
- -1 silane compound Chemical class 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 2
- 229940116269 uric acid Drugs 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 208000007788 Acute Liver Failure Diseases 0.000 description 1
- 206010000804 Acute hepatic failure Diseases 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 208000007082 Alcoholic Fatty Liver Diseases 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 1
- 208000033222 Biliary cirrhosis primary Diseases 0.000 description 1
- 208000028399 Critical Illness Diseases 0.000 description 1
- 206010016262 Fatty liver alcoholic Diseases 0.000 description 1
- 206010019755 Hepatitis chronic active Diseases 0.000 description 1
- 102000002704 Leucyl aminopeptidase Human genes 0.000 description 1
- 108010004098 Leucyl aminopeptidase Proteins 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 208000001940 Massive Hepatic Necrosis Diseases 0.000 description 1
- 208000012654 Primary biliary cholangitis Diseases 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 231100000836 acute liver failure Toxicity 0.000 description 1
- 208000026594 alcoholic fatty liver disease Diseases 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 239000012503 blood component Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 208000022831 chronic renal failure syndrome Diseases 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 238000012921 fluorescence analysis Methods 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 210000004880 lymph fluid Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000006371 metabolic abnormality Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 201000009925 nephrosclerosis Diseases 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 238000003969 polarography Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000011268 retreatment Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 229910000077 silane Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 239000002441 uremic toxin Substances 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
Landscapes
- Investigating Or Analysing Biological Materials (AREA)
Priority Applications (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP13693982A JPS5928496A (ja) | 1982-08-06 | 1982-08-06 | 生体試料の分析方法 |
| CA000433955A CA1220700A (en) | 1982-08-06 | 1983-08-05 | Aqueous solution as an eluant used in liquid chromatography |
| DE8383304555T DE3374604D1 (en) | 1982-08-06 | 1983-08-05 | Eluent for liquid chromatography |
| EP83304555A EP0102769B1 (en) | 1982-08-06 | 1983-08-05 | Eluent for liquid chromatography |
| US06/795,275 US4666861A (en) | 1982-08-06 | 1985-11-05 | Aqueous solution as an eluent used in liquid chromatography |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP13693982A JPS5928496A (ja) | 1982-08-06 | 1982-08-06 | 生体試料の分析方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS5928496A JPS5928496A (ja) | 1984-02-15 |
| JPH0337708B2 true JPH0337708B2 (enrdf_load_stackoverflow) | 1991-06-06 |
Family
ID=15187067
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP13693982A Granted JPS5928496A (ja) | 1982-08-06 | 1982-08-06 | 生体試料の分析方法 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS5928496A (enrdf_load_stackoverflow) |
-
1982
- 1982-08-06 JP JP13693982A patent/JPS5928496A/ja active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| JPS5928496A (ja) | 1984-02-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Eberts et al. | A simplified, colorimetric micromethod for xylose in serum or urine, with phloroglucinol. | |
| Marsilio et al. | Simultaneous HPLC determination with light-scattering detection of lactulose and mannitol in studies of intestinal permeability in pediatrics | |
| JPH02263163A (ja) | 血液試料又は血液から誘導される試料中の血清フルクトサミン濃度を測定する試剤 | |
| André et al. | Two rapid, accurate liquid chromatography tandem mass spectrometry methods for the quantification of seven uremic toxins: An application for describing their accumulation kinetic profile in a context of acute kidney injury | |
| CN113176411B (zh) | 利用唾液检测新型冠状病毒感染的生物标志物及其应用 | |
| CN106066399A (zh) | 检测早期糖尿病肾病的胶体金试纸条的制备方法 | |
| Preeti et al. | Estimation of serum creatinine by routine Jaffé’s method and by dry chemistry in icteric and hemolytic serum samples | |
| JPH06281648A (ja) | アミノグアニジンの分析試験及びその応用 | |
| Martınez-Subiela et al. | Effects of haemolysis, lipaemia, bilirubinaemia and fibrinogen on protein electropherogram of canine samples analysed by capillary zone electrophoresis | |
| JP2004501366A (ja) | 患者の全血、血漿および（または）血清中のアルファ・オキソアルデヒドを検出する方法 | |
| CN102175674A (zh) | 一种检测尿液微量清蛋白的方法 | |
| JPH0337708B2 (enrdf_load_stackoverflow) | ||
| CN113030327B (zh) | 一种基于hplc-ms/ms诊断泌尿结石的试剂盒和应用 | |
| JPH0337709B2 (enrdf_load_stackoverflow) | ||
| Abdullateef et al. | Evaluation of glycated hemoglobin results in different anticoagulant materials and methods | |
| RU2069857C1 (ru) | Способ определения степени поражения почек при нефротическом синдроме | |
| Jarvie et al. | Simple screening tests for the emergency identification of methanol and ethylene glycol in poisoned patients | |
| CN118897083A (zh) | 尿液mt蛋白及其多肽片段在痛风中的应用 | |
| JPS5992349A (ja) | 生体試料の分析法 | |
| Tabatabaei-Malazy et al. | Glycated hemoglobin measurements from dried blood spots: reliability and relation to results obtained from whole blood samples | |
| Severini et al. | Liquid-chromatographic determination of inosine, xanthine, and hypoxanthine in uremic patients receiving hemodialysis treatment. | |
| Liu et al. | Early Diagnostic Value of KIM‐1, NGAL, and NLR in Acute Kidney Injury Caused by Diquat Poisoning | |
| JP3664278B2 (ja) | 血漿または血清試料の調製方法 | |
| Shiomi et al. | Use of immobilized histidine in assay for endotoxin in patients with liver disease | |
| IKEZAKI | Significance of guanidino compounds in Non-Dialyzed patients with chronic renal failure |